Evidence-Based Medicine Sliding Into Market Economy-Based Medicine
Evidence-based medicine was conceived as a safeguard — a commitment to letting rigorous data, rather than tradition or authority, guide clinical decisions. Few would argue with that founding principle. Yet something has shifted. Across cardiology, gastroenterology, and beyond, a pattern is emerging that deserves serious scrutiny: the systematic alignment of clinical evidence with commercial imperatives. The 2024 European Congress of Cardiology lowered its blood pressure thresholds to match American standards, instantly expanding the pool of patients eligible for treatment. Specialists commenting online were blunt about their suspicions: that pharmaceutical market expansion, not improved patient outcomes, was the primary driver. Whether or not that suspicion is entirely fair, the question it raises is legitimate. When diagnostic thresholds shift in ways that consistently favor treatment over watchful waiting, we should ask who benefits. The pattern repeats across drug classes. Each gene...